1. Pink Sheet
  2. >>R&D
  4. >>Real-World Evidence

Real-World Evidence, Digital Health, Insurance Coverage Reforms On Cures 2.0 Agenda

 
• By Derrick Gingery

All three areas need work following enactment of the original 21st Century Cures Act, authors Fred Upton and Diana DeGette write in vision statement.

Capitol House
US Rep. Fred Upton, R-MI, wants a Cures 2.0 bill ready for introduction in early 2020. • Source: Shutterstock

Real-world evidence once again will be among the themes of a congressional effort to streamline and improve access to biomedical innovation.

US Reps. Diana DeGette, D-CO, and Fred Upton, R-MI, are looking for stakeholder and patient ideas to include in another legislative package devoted to drug development and medical research in the same vein as their landmark 21st Century Cures Act. Cures 2.0 will be "an effort to modernize coverage and access to life-saving cures in the United States and across the globe," DeGette and Upton wrote in a 

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Real-World Evidence

UK MHRA’s Clinical Trial Lead On Combined Reviews, The Notification Scheme & Increasing Diversity

 
• By Eliza Slawther

In light of the UK’s MHRA announcing a major overhaul of its clinical trial legislation, the agency’s deputy director for clinical investigations and trials Andrea Manfrin tells the Pink Sheet what sponsors can expect from the new regulation.

EU Health Data Space May Speed Up R&D Through Access To Multi-Omics & Clinical Record Data

 
• By Eliza Slawther

The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.

Why Successful Companies Are ‘Tough On Themselves’ When It Comes To HTA

 
• By Eliza Slawther

Pharmaceutical companies need to “pressure test” their clinical development strategies early for health technology assessment purposes, particularly in light of the new EU HTA Regulation, a life sciences consultant says.

Early Randomization Among Advice On How To Meet Both EMA & HTA Needs

 
• By Neena Brizmohun

Newly published insights from a series of European Medicines Agency workshops can guide drug developers in designing development plans that meet the needs of both regulators and health technology assessment bodies.

More from Clinical Trials